{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:33:55Z","timestamp":1790915635597,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncolytic virotherapy is a promising therapeutic strategy that uses replication-competent viruses to selectively destroy malignancies. However, the therapeutic effect of certain oncolytic viruses (OVs) varies among cancer patients. Thus, it is necessary to overcome resistance to OVs through rationally designed combination strategies. Here, through an anticancer drug screening, we show that DNA-dependent protein kinase (DNA-PK) inhibition sensitizes cancer cells to OV M1 and improves therapeutic effects in refractory cancer models in vivo and in patient tumour samples. Infection of M1 virus triggers the transcription of interferons (IFNs) and the activation of the antiviral response, which can be abolished by pretreatment of DNA-PK inhibitor (DNA-PKI), resulting in selectively enhanced replication of OV M1 within malignancies. Furthermore, DNA-PK inhibition promotes the DNA damage response induced by M1 virus, leading to increased tumour cell apoptosis. Together, our study identifies the combination of DNA-PKI and OV M1 as a potential treatment for cancers.<\/jats:p>","DOI":"10.1038\/s41467-018-06771-4","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T10:51:19Z","timestamp":1539341479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["RETRACTED ARTICLE: DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage"],"prefix":"10.1038","volume":"9","author":[{"given":"Xiao","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"6771_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2013.07.010","volume":"59","author":"HT Ong","year":"2013","unstructured":"Ong, H. T. et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. Hepatol. 59, 999\u20131006 (2013).","journal-title":"J. Hepatol."},{"key":"6771_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"6771_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11262-007-0110-3","volume":"35","author":"JS Wen","year":"2007","unstructured":"Wen, J. S. et al. Genomic analysis of a Chinese isolate of Getah-like virus and its phylogenetic relationship with other Alphaviruses. Virus Genes 35, 597\u2013603 (2007).","journal-title":"Virus Genes"},{"key":"6771_CR4","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.4161\/cc.8.20.9832","volume":"8","author":"J Hu","year":"2009","unstructured":"Hu, J., Cai, X. F. & Yan, G. Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolar translocation of p21WAF1\/CIP1 protein. Cell Cycle 8, 3328\u20133339 (2009).","journal-title":"Cell Cycle"},{"key":"6771_CR5","doi-asserted-by":"publisher","first-page":"eaam7996","DOI":"10.1126\/scitranslmed.aam7996","volume":"9","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 9, eaam7996 (2017).","journal-title":"Sci. Transl. Med."},{"key":"6771_CR6","doi-asserted-by":"publisher","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","volume":"111","author":"Y Lin","year":"2014","unstructured":"Lin, Y. et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl. Acad. Sci. USA 111, E4504\u2013E4512 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6771_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/hum.2016.038","volume":"27","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Naturally existing oncolytic virus M1 Is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Hum. Gene Ther. 27, 700\u2013711 (2016).","journal-title":"Hum. Gene Ther."},{"key":"6771_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836\u2013848 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"6771_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/sj.onc.1209055","volume":"25","author":"R Cesaire","year":"2006","unstructured":"Cesaire, R. et al. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene 25, 349\u2013358 (2006).","journal-title":"Oncogene"},{"key":"6771_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","volume":"4","author":"DF Stojdl","year":"2003","unstructured":"Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell. 4, 263\u2013275 (2003).","journal-title":"Cancer Cell."},{"key":"6771_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","volume":"254","author":"MJ Vaha-Koskela","year":"2007","unstructured":"Vaha-Koskela, M. J., Heikkila, J. E. & Hinkkanen, A. E. Oncolytic viruses in cancer therapy. Cancer Lett. 254, 178\u2013216 (2007).","journal-title":"Cancer Lett."},{"key":"6771_CR12","doi-asserted-by":"publisher","first-page":"14981","DOI":"10.1073\/pnas.0803988105","volume":"105","author":"TL Nguyen","year":"2008","unstructured":"Nguyen, T. L. et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. USA 105, 14981\u201314986 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6771_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/mt.2015.172","volume":"24","author":"K Li","year":"2016","unstructured":"Li, K. et al. Activation of cyclic adenosine monophosphate pathway increases the sensitivity of cancer cells to the oncolytic virus M1. Mol. Ther. 24, 156\u2013165 (2016).","journal-title":"Mol. Ther."},{"key":"6771_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/sj.mt.6300343","volume":"16","author":"J Altomonte","year":"2008","unstructured":"Altomonte, J. et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol. Ther. 16, 146\u2013153 (2008).","journal-title":"Mol. Ther."},{"key":"6771_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/sj.mt.6300076","volume":"15","author":"I Haralambieva","year":"2007","unstructured":"Haralambieva, I. et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther. 15, 588\u2013597 (2007).","journal-title":"Mol. Ther."},{"key":"6771_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7410","volume":"6","author":"R Arulanandam","year":"2015","unstructured":"Arulanandam, R. et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat. Commun. 6, 6410 (2015).","journal-title":"Nat. Commun."},{"key":"6771_CR17","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.0400567101","volume":"101","author":"HM Chang","year":"2004","unstructured":"Chang, H. M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101, 9578\u20139583 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6771_CR18","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1172\/JCI80713","volume":"125","author":"H Nakashima","year":"2015","unstructured":"Nakashima, H. et al. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J. Clin. Invest. 125, 4269\u20134280 (2015).","journal-title":"J. Clin. Invest."},{"key":"6771_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2974","volume":"4","author":"F Le Boeuf","year":"2013","unstructured":"Le Boeuf, F. et al. Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat. Commun. 4, 1974 (2013).","journal-title":"Nat. Commun."},{"key":"6771_CR20","doi-asserted-by":"publisher","first-page":"e00047","DOI":"10.7554\/eLife.00047","volume":"1","author":"BJ Ferguson","year":"2012","unstructured":"Ferguson, B. J., Mansur, D. S., Peters, N. E., Ren, H. & Smith, G. L. DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. eLife 1, e00047 (2012).","journal-title":"eLife"},{"key":"6771_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0006-2952(02)01165-6","volume":"64","author":"MJ Servant","year":"2002","unstructured":"Servant, M. J., Grandvaux, N. & Hiscott, J. Multiple signaling pathways leading to the activation of interferon regulatory factor 3. Biochem. Pharmacol. 64, 985\u2013992 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"6771_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4419-6306-2_17","volume":"678","author":"RJ Tallarida","year":"2010","unstructured":"Tallarida, R. J. Combination analysis. Adv. Exp. Med. Biol. 678, 133\u2013137 (2010).","journal-title":"Adv. Exp. Med. Biol."},{"key":"6771_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1126\/science.aak9654","volume":"355","author":"BL Sibanda","year":"2017","unstructured":"Sibanda, B. L., Chirgadze, D. Y., Ascher, D. B. & Blundell, T. L. DNA-PKcs structure suggests an allosteric mechanism modulating DNA double-strand break repair. Science 355, 520\u2013524 (2017).","journal-title":"Science"},{"key":"6771_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.dnarep.2004.03.021","volume":"3","author":"S Burma","year":"2004","unstructured":"Burma, S. & Chen, D. J. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair 3, 909\u2013918 (2004).","journal-title":"DNA Repair"},{"key":"6771_CR25","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1078-0432.CCR-14-0842","volume":"21","author":"L Cornell","year":"2015","unstructured":"Cornell, L. et al. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin. Cancer Res. 21, 925\u2013933 (2015).","journal-title":"Clin. Cancer Res."},{"key":"6771_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ccell.2015.06.004","volume":"28","author":"JF Goodwin","year":"2015","unstructured":"Goodwin, J. F. et al. DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis. Cancer Cell. 28, 97\u2013113 (2015).","journal-title":"Cancer Cell."},{"key":"6771_CR27","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1021\/jm050444b","volume":"48","author":"IR Hardcastle","year":"2005","unstructured":"Hardcastle, I. R. et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J. Med. Chem. 48, 7829\u20137846 (2005).","journal-title":"J. Med. Chem."},{"key":"6771_CR28","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1158\/0008-5472.CAN-05-4275","volume":"66","author":"Y Zhao","year":"2006","unstructured":"Zhao, Y. et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66, 5354\u20135362 (2006).","journal-title":"Cancer Res."},{"key":"6771_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1254\/jphs.11181FP","volume":"118","author":"Y Liu","year":"2012","unstructured":"Liu, Y. et al. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J. Pharmacol. Sci. 118, 423\u2013432 (2012).","journal-title":"J. Pharmacol. Sci."},{"key":"6771_CR30","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1021\/jm800295d","volume":"51","author":"AJ Folkes","year":"2008","unstructured":"Folkes, A. J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522\u20135532 (2008).","journal-title":"J. Med. Chem."},{"key":"6771_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527\u20131538 (2015).","journal-title":"Cell"},{"key":"6771_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ncb0311-184","volume":"13","author":"I Tabas","year":"2011","unstructured":"Tabas, I. & Ron, D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13, 184\u2013190 (2011).","journal-title":"Nat. Cell Biol."},{"key":"6771_CR33","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1172\/JCI38857","volume":"119","author":"JM Timmins","year":"2009","unstructured":"Timmins, J. M. et al. Calcium\/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J. Clin. Invest. 119, 2925\u20132941 (2009).","journal-title":"J. Clin. Invest."},{"key":"6771_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe, S. T. & Mossman, K. L. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol. Ther. 22, 251\u2013256 (2014).","journal-title":"Mol. Ther."},{"key":"6771_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"6771_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cdd.2013.75","volume":"21","author":"I Martins","year":"2014","unstructured":"Martins, I. et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 21, 79\u201391 (2014).","journal-title":"Cell Death Differ."},{"key":"6771_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/jnci\/djr509","volume":"104","author":"R Kanai","year":"2012","unstructured":"Kanai, R. et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J. Natl. Cancer Inst. 104, 42\u201355 (2012).","journal-title":"J. Natl. Cancer Inst."},{"key":"6771_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nprot.2006.5","volume":"1","author":"PL Olive","year":"2006","unstructured":"Olive, P. L. & Banath, J. P. The comet assay: a method to measure DNA damage in individual cells. Nat. Protoc. 1, 23\u201329 (2006).","journal-title":"Nat. Protoc."},{"key":"6771_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.dnarep.2006.01.011","volume":"5","author":"B Mukherjee","year":"2006","unstructured":"Mukherjee, B. et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair. 5, 575\u2013590 (2006).","journal-title":"DNA Repair."},{"key":"6771_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-11-18","volume":"11","author":"J An","year":"2010","unstructured":"An, J. et al. DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression. BMC Mol. Biol. 11, 18 (2010).","journal-title":"BMC Mol. Biol."},{"key":"6771_CR41","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/sj.mt.6300193","volume":"15","author":"JA Noser","year":"2007","unstructured":"Noser, J. A. et al. The RAS\/Raf1\/MEK\/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells Mol. Ther. 15, 1531\u20131536 (2007).","journal-title":"Mol. Ther."},{"key":"6771_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1535-6108(03)00330-1","volume":"5","author":"S Balachandran","year":"2004","unstructured":"Balachandran, S. & Barber, G. N. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell. 5, 51\u201365 (2004).","journal-title":"Cancer Cell."},{"key":"6771_CR43","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","volume":"6","author":"DF Stojdl","year":"2000","unstructured":"Stojdl, D. F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821\u2013825 (2000).","journal-title":"Nat. Med."},{"key":"6771_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.virol.2004.08.039","volume":"330","author":"M Ahmed","year":"2004","unstructured":"Ahmed, M., Cramer, S. D. & Lyles, D. S. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330, 34\u201349 (2004).","journal-title":"Virology"},{"key":"6771_CR45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/sj.cgt.7700794","volume":"12","author":"O Ebert","year":"2005","unstructured":"Ebert, O., Harbaran, S., Shinozaki, K. & Woo, S. L. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene. Ther. 12, 350\u2013358 (2005).","journal-title":"Cancer Gene. Ther."},{"key":"6771_CR46","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3399","volume":"12","author":"NJ Curtin","year":"2012","unstructured":"Curtin, N. J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 12, 801\u2013817 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"6771_CR47","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1158\/1078-0432.CCR-11-2325","volume":"18","author":"JP Nuesch","year":"2012","unstructured":"Nuesch, J. P., Lacroix, J., Marchini, A. & Rommelaere, J. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin. Cancer Res. 18, 3516\u20133523 (2012).","journal-title":"Clin. Cancer Res."},{"key":"6771_CR48","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1242\/jcs.02981","volume":"119","author":"DE Wilkinson","year":"2006","unstructured":"Wilkinson, D. E. & Weller, S. K. Herpes simplex virus type I disrupts the ATR-dependent DNA damage response during lytic infection. J. Cell Sci. 119, 2695\u20132703 (2006).","journal-title":"J. Cell Sci."},{"key":"6771_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tim.2007.01.003","volume":"15","author":"CE Lilley","year":"2007","unstructured":"Lilley, C. E., Schwartz, R. A. & Weitzman, M. D. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol. 15, 119\u2013126 (2007).","journal-title":"Trends Microbiol."},{"key":"6771_CR50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/leu.2010.6","volume":"24","author":"LJ Mah","year":"2010","unstructured":"Mah, L. J., El-Osta, A. & Karagiannis, T. C. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24, 679\u2013686 (2010).","journal-title":"Leukemia"},{"key":"6771_CR51","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"6771_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","volume":"79","author":"MR Lieber","year":"2010","unstructured":"Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181\u2013211 (2010).","journal-title":"Annu. Rev. Biochem."},{"key":"6771_CR53","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz, L. M. & Zou, L. Molecular pathways: targeting ATR in cancer therapy. Clin. Cancer Res. 21, 4780\u20134785 (2015).","journal-title":"Clin. Cancer Res."},{"key":"6771_CR54","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","volume":"14","author":"Y Shiloh","year":"2013","unstructured":"Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197\u2013210 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."}],"updated-by":[{"DOI":"10.1038\/s41467-025-65397-5","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06771-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06771-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06771-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:03:10Z","timestamp":1761325390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06771-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["6771"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-06771-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-65397-5","URL":"https:\/\/doi.org\/10.1038\/s41467-025-65397-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4342"}}